Answers are grounded in this paper and cite their sources.
Anaemia affects approximately 73% of multiple myeloma (MM) patients and serves as an independent predictor of reduced quality of life and poor survival. This review synthesizes recent advances in understanding the multifactorial aetiology of MM-associated anaemia, emphasizing the central role of a dysregulated bone marrow microenvironment. Key mechanisms include (a) cytokine network imbalances that serve as central initiating and perpetuating events, impairing erythroid differentiation via GATA-1 suppression; (b) inadequate compensatory erythropoietin (EPO) production despite hypoxia; (c) malignant plasma cell cytotoxicity through Fas-L/TRAIL-mediated apoptosis of erythroid progenitors; and (d) hepcidin-driven iron restriction via BMP/IL-6 signalling in hepatocytes. Building on these pathophysiologic insights, we then present a structured therapeutic framework, operationalized through a target mapping table that systematically catalogues a hierarchy of therapies, providing a translational roadmap from mechanism to individualized treatment. We critically evaluate anaemia management strategies, including conventional approaches, such as erythropoiesis-stimulating agents (ESAs), iron supplementation, and transfusion. These limitations may signal microenvironment-driven anaemia and guide targeted intervention. At the foundation are tumour‑clearing strategies, where anti‑CD38 antibodies exemplify how deep remission drives haematopoietic recovery. BCMA-directed CAR‑T cells and bispecific antibodies (BsAbs), while capable of purifying the microenvironment, introduce a therapeutic paradox. Their potent antimyeloma effect is frequently accompanied by immune effector cell‑associated haematotoxicity, including significant anaemia. Next are strategies that block erythropoiesis‑suppressive signals, notably those targeting the CCL3/p38/GATA‑1 axis and hepcidin overexpression. Further downstream lie approaches aimed at restoring the erythroid niche. Individualized, biomarker‑driven strategies targeting the dominant microenvironmental defect offer a pathway toward durable correction of anaemia in MM patients while controlling disease progression.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: